ClinicalTrials.gg
RecruitingNCT06302491Updated Feb 27, 2026

A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia

A Phase 2 interventional study of AND017 capsules and AND017 Placebo in β -Thalassemia, sponsored by Kind Pharmaceuticals LLC. Recruiting at 5 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Kind Pharmaceuticals LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Thalassemia with a site in China — 12 open to participants now, 14 under way, none of them phase 3. Thalassemia · China.

Planned enrollment
12th of 27
64 · median 30
Started
2024
with 7 others
Phase 2
9 of 32
4 open now
Primary completion
2026-12
later than 5 of 13 live
Registered
22nd of 32
by date

Among the 32 studies in Thalassemia with a site in China, this one is the 12th largest by planned enrollment of the 27 interventional ones that give a count, is one of 8 that started in 2024, is one of 9 in phase 2, reaches primary completion later than 5 of the 13 other live ones, and was the 22nd registered.

Thalassemia

250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.

Browse Thalassemia studies →

Open to participants now

12 of the 32 studies in Thalassemia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 28 Thalassemia studies recruiting now, 7 (25%) set no upper age limit and 18 (64%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Thalassemia with a site in China, or all of them as a file.
02

Study summary

This is a phase II, randomized, double-blinded, placebo-controlled study to treat patients with transfusion-dependent and non-transfusion dependent β -thalassemia with AND017 and optimal supportive care, including blood transfusion and iron removal, based on the clinician's judgment and practice.

03

Conditions studied

  • β -Thalassemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Documented diagnosis of β-thalassemia or E/β-thalassemia, HbS/ β-thalassemia (β-thalassemia with α-bead mutation and/or multiplication is not allowed).
  2. TDT subjects: receive regular blood transfusions, defined as 6-20 RBC units (including threshold) in the 24 weeks prior to screening assessment, and no transfusion-free period of ≥ 5 weeks during this period.
  3. NTDT cohort: having transfused \<6 RBC units in the 24 weeks prior to the screening assessment, no regular transfusion schedule, and no transfusion for 4 weeks prior to the screening assessment.
  4. Subject transfusion records should be obtained within 24 weeks prior to the screening assessment, containing the date of transfusion, transfused RBC units, and pre-transfusion hemoglobin values.
  5. score 0-1.
  6. NTDT subjects with Hb ≤ 10.0 g/dL at screening test and one follow-up test (two tests more than one week apart) and difference in values between the two tests ≤ 1.0 g/dL.
  7. Adequate liver function: Total \< 1.5 x (ULN) (subjects with Gilbert syndrome, i.e., unconjugated hyperbilirubinemia, have a total bilirubin \< 3 x ULN),

Exclusion criteria

Exclusion Criteria:

  1. Other causes of anemia (e.g., hemolytic anemia, history of pure red blood cell aplastic anemia, myelodysplastic syndrome, or multiple myeloma)
  2. Presence of active infection or inflammatory disease requiring systemic anti-infective therapy, including concomitant diseases with inflammatory symptoms (e.g. generalized erythema, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, dry syndrome, etc.)
  3. Complicated retinal neovascularization requiring treatment (diabetic proliferative retinopathy, age-related exudative macular degeneration, retinal vein occlusion, macular edema, etc.)
  4. Inability to take oral medications, conditions with a history of gastrectomy/bowel resection that may have an effect on the absorption of gastrointestinal medications (excluding gastric polyps or colonic polypectomy), or gastroparesis that remains symptomatic on current therapy
  5. bleeding (requiring emergency blood transfusion within 12 h or a decrease in ≥ 2 g/dL within one week) within 4 weeks prior to the first dose, or a tendency to bleed or risk of bleeding that has not been medically or surgically corrected
  6. Uncontrolled hypertension, defined as a diastolic blood pressure value >95 mmHg or a systolic blood pressure >160 mmHg on 2 or more of 3 repeated blood pressure tests (each at least 5 minutes apart) during the screening period
  7. Complicated congestive heart failure ( [NYHA] class III or higher).
  8. history of stroke, (TIA), myocardial infarction, thromboembolic event (deep vein thrombosis, DVT), pulmonary embolism, or pulmonary infarction within 24 weeks prior to screening evaluation
  9. history of significant coagulation abnormalities, or count >600 x 109/L or \<80 x 109/L
  10. History of epilepsy or any past seizures.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    AND017 capsules 8 mg

    Drug: AND017 capsules

  • Experimental
    AND017 capsules 12 mg

    Drug: AND017 capsules

  • Experimental
    AND017 capsules 16 mg

    Drug: AND017 capsules

  • Placebo comparator
    AND017 Placebo capsules

    Drug: AND017 Placebo

Interventions

  • Administer AND017 capsules once per day (QD)

  • DrugAND017 Placebo

    Administer AND017 matching placebo capsules once per day (QD)

06

What researchers measure

Primary outcomes

  1. Evaluate the safety and tolerability of different oral doses of AND017 in the treatment of β-thalassemia subjects

    Evaluate the safety and tolerability of different oral doses of AND017 in the treatment of β-thalassemia subjects by AE rate by CTCAE 5.0

    Time frame: From baseline to Week 24 or End of Treatment if discontinue early

Secondary outcomes

  1. Change in mean Hb levels relative to baseline at weeks 8-12 and week 20-24 post-treatment compared to baseline (mean Hb values during the 4 weeks prior to the first dose).

    For NTDT cohort, evaluation of the effect of AND017+BSC on Hb levels.

    Time frame: Baseline, Week 8-12, Week 20-24

  2. The level of Hb and the change from baseline at each visit throughout the treatment period.

    For NTDT cohort, evaluation of the effect of AND017+BSC on Hb levels.

    Time frame: From baseline to Week1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24

  3. Proportion of patients with mean Hb elevation ≥1.0 g/dL from baseline to weeks 8-12 after dosing.

    For NTDT cohort, evaluation of the effect of AND017+BSC on Hb levels.

    Time frame: Baseline, Week 8-12

  4. Levels of and changes from baseline in red blood cell count throughout the treatment period

    For NTDT cohort, Evaluation of the effect of AND017+BSC on RBC count

    Time frame: From baseline to Week1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24

  5. Levels of and changes from baseline in reticulocyte count throughout the treatment period

    For NTDT cohort, Evaluation of the effect of AND017+BSC on reticulocyte count

    Time frame: From baseline to Week1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24

  6. Levels of and changes from baseline in mean corpuscular volume (MCV) throughout the treatment period

    For NTDT cohort, Evaluation of the effect of AND017+BSC on the MCV

    Time frame: From baseline to Week1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24

  7. Levels of and changes from baseline in mean corpuscular hemoglobin (MCH) throughout the treatment period

    For NTDT cohort, Evaluation of the effect of AND017+BSC on MCH

    Time frame: From baseline to Week1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24

  8. Levels of and changes from baseline in mean corpuscular hemoglobin concentration (MCHC) throughout the treatment period

    For NTDT cohort, Evaluation of the effect of AND017+BSC on MCHC

    Time frame: From baseline to Week1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24

  9. Throughout the treatment period, changes in the levels and relative baseline of transferrin will be assessed.

    For NTDT cohort, evaluation of the effect of AND017+BSC on transferrin level

    Time frame: From baseline to Week 4, 8, 12, 16, 20, 24

  10. Throughout the treatment period, changes in the levels and relative baseline of transferrin saturation (TSAT) will be assessed.

    For NTDT cohort, evaluation of the effect of AND017+BSC on TSAT.

    Time frame: From baseline to Week 4, 8, 12, 16, 20, 24

  11. Throughout the treatment period, changes in the levels and relative baseline of ferritin will be assessed.

    For NTDT cohort, evaluation of the effect of AND017+BSC on ferritin

    Time frame: From baseline to Week 4, 8, 12, 16, 20, 24

  12. Throughout the treatment period, changes in the levels and relative baseline of serum iron level will be assessed.

    For NTDT cohort, evaluation of the effect of AND017+BSC on serum iron level

    Time frame: From baseline to Week 4, 8, 12, 16, 20, 24

  13. Throughout the treatment period, changes in the levels and relative baseline of total iron binding capacity (TIBC) will be assessed.

    For NTDT cohort, evaluation of the effect of AND017+BSC on TIBC

    Time frame: From baseline to Week 4, 8, 12, 16, 20, 24

  14. Change in transfusion load (units transfused) at 12-24 weeks post-dose compared to baseline (12 weeks to W0 before first dose).

    For TDT cohort, evaluate changes in mean transfusion load by AND017+BSC at 12 to 24 weeks after dosing

    Time frame: Baseline, Week 20-24, or End of Treatment if discontinue early

  15. Change in number of transfusions at 12-24 weeks post-dose compared to baseline (12 weeks to W0 before first dose).

    For TDT cohort, evaluate changes in mean transfusion load by AND017+BSC at 12 to 24 weeks after dosing

    Time frame: Baseline and Week 20-24

  16. Proportion of subjects with ≥33% reduction in transfusion load (transfusion units) relative to baseline (12 weeks prior to first dose to W0) from baseline to any consecutive 12-week period after dosing.

    For TDT cohort, proportion of subjects with ≥33% reduction in transfusion load (transfusion units) relative to baseline (12 weeks prior to first dose to W0) from baseline to any consecutive 12-week period after dosing.

    Time frame: Baseline, Week 0-12, 2-14, 4-16, 6-18, 8-20, 10-22, and 12-24

  17. Duration (days) of maintenance below this transfusion dose after a 33% reduction in transfusion load from baseline has been achieved.

    For TDT cohort, duration (days) of maintenance below this transfusion dose after a 33% reduction in transfusion load from baseline has been achieved.

    Time frame: From baseline to Week 24 or End of Treatment if discontinue early

07

Study locations

4 of 5 sites recruiting
  • Nanfang Hospital Southern Medical University
    Guangzhou, Guangdong 510515, China
    Not yet recruiting
    • Lin Jiang, MD · Principal investigator
  • Maoming People's Hospital
    Maoming, Guangdong 525000, China
    Recruiting
    • Xiong Zhang, MD · Principal investigator
  • Liuzhou People's Hospital
    Liuzhou, Guangxi 545006, China
    Recruiting
    • Min Wei, MD · Principal investigator
  • Guangxi Medical University No.1 Affiliated Hospital
    Nanning, Guangxi 530021, China
    Recruiting
    • Yongrong Lai, MD · Principal investigator
  • Hainan General Hospital
    Haikou, Hainan 570203, China
    Recruiting
    • Guyun Wang, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 25 phase 2 interventional studies under Thalassemia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 67. This study's planned 31 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2023
First posted
Mar 8, 2024
StartActual
May 27, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Jul 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06302491
Lead sponsor
Kind Pharmaceuticals LLC
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
May 27, 2024
Primary completion
Dec 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Yusha Zhu, MD, PhD
Contact
yushazhu@kindpharmaceutical.com
6467252552
Yusha Zhu, MD, PhD
study director · Kind Pharmaceuticals LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AND017

Start the discussion